NIFTY  8,422.35  0.11%
  SENSEX  27,323.00  0.13%
 CURRENCY  Rs  68.10/$ 72.21/€, 82.03/£
  GOLD  28,604.00  0.26%
  SILVER  41,155.00  0.48%
  DAX  11,554.70  -0.64%
  FTSE  7,327.13  -0.15%
  CAC  4,882.18  -0.73%
  HANG SENG  22,718.20  -0.96%
  NIKKEI  19,095.20  -1.00%
  Shanghai Composite  3,103.43  -0.17%
  DOW JONES  19,885.70  -0.03%
  NASDAQ  5,574.12  0.48%
  S&P 500  2,274.64  0.18%
HPCL CMD TO BTVI : Card Transaction Charge Will Be Bourne By OMCs & Banks HPCL CMD TO BTVI : Petrol Pump Dealers & Consumers May Not Pay For Card Transaction Charge HPCL CMD TO BTVI : Gasoline Performance Was Better In Q3 Compared To Q2

Merck, Cipla Avoiding Compulsory License?

Video:

Play this video

February 26: In a bid to skirt compulsory licenses issued by the Indian government, foreign drug makers are tying up with local partners to sign exclusive product licensing deals. The most recent instance seems of the agreement between Merck and Cipla to market the AIDS drug Raltegravir in India.